HLA-C and neoplasm: PCa is characterized by a low tumor mutational burden (TMB), thus revealing a poor collection of neoepitopes crucial for immune cell attraction to the tumor sites, epitope–MHC interactions and activation of TILs by antigen-presenting cells [5, 27].